***** FACSIMILE COVER SHEET *****

APR 07 '06 12:41

Message To:				
=====================================				
Message From:				
203 791 6183				

08
Pages
Follow This Cover Page

RECEIVED CENTRAL FAX CENTER APR 07 2006

Telefax



Central Fax United States Patent and Trademark Office Boehringer Ingelheim Pharmaceuticals Inc.

571-273-8300

Page 1 of 8

April 07, 2006

Serial No.: Atty. Docket.: 1/1387

10/647,156

Filed: Art Unit: 8/22/2003

1624

Kellyann Parrillo Telephone 203-778-7816 Telefax 203-798-4408 E-Mail kparrill@rdg.boehringeringelheim.com

900 Ridgebury Rd/P.O. Box 368 Ridgefield, CT 06877-0368

Dear SIR;

Please find transmitted herewith a Transmittal Letter Requesting Correction of Response Submitted with Incorrect Serial Number, a copy of the original submission, including postcard and petition for extension of time for a total of eight pages including this cover page.

Should you not receive all eight pages of this transmission, please contact me at 203-778-7816. Thank you.

Best regards,

Kellyano Parrillo

Administrative Assistant to David A. Dow, Reg. No. 46,124

IP Counsel, II

Boehringer Ingelheim Pharmaceuticals, Inc.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Stenkamp et al) Art Unit: 1624

Serial No: 10/647,156) Examiner: Truong, Tamthom,

Filed: 08/22/2003) Docket No.: 1/1387

For: New Carboxamide Compounds having Melanin Concentrating Hormone Antagonistic Activity, Pharmaceutical Preparations Comprising these Compounds and Process for their Manufacture

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER REQUESTING CORRECTION OF RESPONSE SUMBITTED WITH INCORRECT SERIAL NUMBER

Sir:

Applicant replied to the restriction requirement in the instant application on March 14, 2006 listing the incorrect serial number (10/402,017) on the response. The return postcard that was submitted had the correct serial number. Applicant contacted the Examiner (Tanthom Truong) in the instant case on March 22, 2006 in attempt to remedy the error. The Examiner suggested that the Response may shortly thereafter be correctly routed by the Examiner of the case with the incorrect serial number. When applicant checked the status of the case on the PAIR system this did not seem to occur. Applicant contacted Examiner Truong again on April 7, 2006 and the Examiner indicated that the routing of the response may have been complicated by fact that the response included an extension of time. Applicant requests that if the payment of the extension of time had been applied to SN 10/402, 017 that the payment be transferred to the correct case SN 10,647,156. It is believed that an additional month extension is not necessary since the Response was sent, albeit with the wrong SN on the paper. However, if additional

extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a) and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 02-2955.

A copy of the Response (with the corrected Serial Number) and return post card sent on March 14, 2006 are submitted herein.

Respectfully submitted,

APR 07 '06 12:42 FR 203 791 6183

David A. Dow

Attorney for Applicant(s)

Reg. No. 46,124

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 791-6214

Docket No. 1/1387

Certificate of Transmission

I hereby certify that this correspondence is being transmitted to the USPTO at Facsimile #571-273-8300:

on April 7, 2006

David A. Dow, Reg. 46,124

APPLIC T(S):

Dirk STENKAMP et al

SERIAL NO.:

10/647,156

CONFIRMATION NO.: 1272

1272

FILING DATE:

August 22, 2003

DOCKET NO.:

1/1387

TITLE:

NEW CARBOXAMIDE

COMPOUNDS HAVING MELANIN

CONCENTRATING HORMONE ANTAGONISTIC
ACTIVITY, PHARMACEUTICAL PREPARATIONS
COMPRISING THESE CONTOURNES AND

COMPRISING THESE COMPOUNDS AND PROCESS FOR THEIR MANUFACTURE

VIN CONNECTION WITH THE ABOVE CASE, PLEASE DATE STAMP TO ACKNOWLEDGE RECEIPT OF THE DOCUMENTS LISTED BELOW, AND RETURN TO ADDRESSEE.

- Response to Restriction Requirement dated 12/14/2005 (3 pages)
- Petition for Extension of Time Under 37 CFR 1.136(a) (1 page)

Mailed: March 14, 2006



CENTRAL FAX CENTER

APR 07 2006





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Stenkamp et al)	Art Unit:	1624
Serial No:	\0 647,156)	Examiner:	Truong, Tamthom
Filed:	08/22/2003	•	Docket No :	1/1397

For: New Carboxamide Compounds having Melanin Concentrating Hormone Antagonistic Activity, Pharmaceutical Preparations Comprising these Compounds and Process for their Manufacture

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

The Examiner imposed a restriction requirement in the instant application. The Examiner alleged that the claims of the instant application include 16 different groups including Groups I and Group II as follows:

Group I: Claims 1-3, 6, 9-11, 13, 16, 20-23, 26-30, 32 and 44 drawn to compounds the wherein formula I is formula I-1 and pharmaceutical composition thereof.

Group II: Claims 1-3, 6, 9-11, 13, 16, 20-23, 26-30, 32 and 44 drawn to compounds wherein formula I is I-2 and pharmaceutical composition thereof.

In response to that restriction requirement, applicants hereby elect with <u>traverse</u> to prosecute in this application the subject matter of Group I, claims 1-3, 6, 9-11, 13, 16, 20-23, 26-30, 32 and 44. Applicants submit that Groups I and II wherein the groups and substituents are defined as in the specification page 49 and 50 are sufficiently related

PAGE 6/9 * RCVD AT 4/7/2006 12:21:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/7 * DNIS:2738300 * CSID:203 791 6183 * DURATION (mm-ss):02-10





such that the search for relevant art for one Group would be expected to uncover prior art that is relevant to the other Group, since Group I and Group II involve substantially the same components. Thus, a search for relevant art and subsequent examination would not be an undue burden on the Examiner and restriction should be withdrawn. M.P.E.P. §803. It is therefore respectfully requested that the Examiner reconsider the restriction and advance the subject matter of Groups I and II for prosecution.

The common structural elements in the above formulae I-1 and I-2 are:

- the amine group connected via a spacer group X to the group Y which is phenyl (U=CH) or pyridyl (U=N);
- the amide group is linked to the group Y via an ethylene spacer,
- the group A-B (being biphenyl or pyridyl-phenyl) is linked to the carbonyl-group of the amide-group.

The flexibility in the group Y, i.e. phenyl or pyridyl, whereby the pyridyl may be oriented according to the formula I-1 or I-2, is illustrated by the following examples:

Example	Structure	IC ₅₀ (nM)
2,1 (page 146)	Ch Ch Ch	< 20 nM
2,118 (page 270)	CN N=>-N+	< 20 nM
2,119 (page 274)		< 20 nM

PAGE 7/9 * RCVD AT 4/7/2006 12:21:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/7 * DNIS:2738300 * CSID:203 791 6183 * DURATION (mm-ss):02-10



Applicants reserve the right to prosecute in one or more divisional applications whatever subject matter is not examined or allowed here.

Authorization for payment of fees for a two month extension of time for reply to the Office Action is hereby given. Is not believed that any other fees are required beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. §1.136(a) and any fees required therefore are hereby authorized to be charged to our Deposit Account No. 02-2955.

Respectfully submitted,

David A. Dow

Attorney for Applicant(s)

Reg. No. 46,124

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 791-6214

Docket No. 1/1387

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

on March 14, 2006

David A. Dow, Reg. 46,124

CENTRAL FAX CENTER

APR 07 2000





Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.

DETERMINED EXPENSION OF THE	E LINDED 27 CED 4 426/-\	Docket Number (Option	al)			
PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)		, ,				
	FY 2005 (Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)		1387			
Application Number 10/402,017		Filed 8/22/2003				
FOR COMPOUNDS AND PROCESS FOR THEIR MANUFACTU	CONCENTRATING HORMONE ANTAGONISTIC ACT IRE	IVITY, PHARMACEUTICAL PREPA	RATIONS COMPRISING THESE			
Art Unit 1624	,	Examiner Truong, Ta	amthom			
This is a request under the provisions of 3 application.	This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified					
The requested extension and fee are as for	illows (check time period desired a	nd enter the appropriat	e fee below):			
	<u>Fee</u>	Small Entity Fee				
One month (37 CFR 1.17(a)((1)) \$120	\$60	\$			
Two months (37 CFR 1.17(a)(2)) \$450	\$225	s_450.00			
Three months (37 CFR 1.17)	(a)(3)) \$1020	\$510	s			
Four months (37 CFR 1.17(a	a)(4)) \$1590	\$795	\$			
Five months (37 CFR 1.17(a	(5)) \$2160	\$1080	s			
Applicant claims small entity status. S	see 37 CFR 1.27.					
A check in the amount of the fee is	s enclosed.		`			
Payment by credit card. Form PTC	O-2038 is attached.		•			
The Director has already been au	thorized to charge fees in this a	pplication to a Depor	sit Account.			
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number						
WARNING: Information on this form me Provide credit card information and aut	ay become public. Credit card information on PTO-2038.	ation should not be incl	luded on this form.			
			•			
I am the applicant/inventor.						
Statement unde	of the entire interest. See 37 C r 37 CFR 3.73(b) is enclosed (F	orm PTO/SB/96).				
attorney or agent of record. Registration Number 46,124						
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34						
Jan Jon		March 14, 200	06			
Signatur	e	Date				
David A. Dow		203-791-6214	<u> </u>			
Typed or printe	ed name	Teleph	none Number			
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
Total of	forms are submitted.					
This collection of information is required by 37 CFR 1.1	36(a). The information is required to obtain	or retain a benefit by the publi	ic which is to file (and by the			

USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestors for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissionar for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PAGE 9/9 * RCVD AT 4/7/2006 12:21:13 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-5/7 * DNIS:2738300 * CSID:203 791 6183 * DURATION (mm-ss):02-10 GE 208 ***